- In a few days, Moderna Inc MRNA 2.8% will start a trial designed to evaluate pregnancy outcomes in women after receiving the Company's COVID-19 shot during their pregnancy.
- According to an update posted on the ClinicalTrials.gov website, the trial will begin on July 22, targeting the enrollment of 1,000 participants.
- The observational study with a 21-month follow-up period is expected to complete in January 2024.
- During the period, the primary data from pregnant women and their healthcare providers will be collected for the study.
- The Centers for Disease Control and Prevention recommended that pregnant females receive the messenger-RNA-based COVID-19 vaccines developed by Pfizer Inc PFE 0.33%/ BioNTech SE BNTX 0.79% and Moderna.
- Also, Monday, Moderna announced a supply agreement with the government of Argentina for 20 million doses of its COVID-19 vaccine or its updated variant booster vaccine candidate, if authorized.
- Delivery will start from 1Q of 2022.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.